OBJECTIVE: To determine the comparative effects of the @entity12721 ( @entity6170 and @entity12098 ) on @entity583 , @entity712 , and mortality in @entity1 with @entity164 2 @entity6 . DESIGN: Systematic review and meta-analysis of observational studies. DATA SOURCES: Searches of Medline and Embase in September 2010. STUDY SELECTION: Observational studies that directly compared the risk of cardiovascular outcomes for @entity6170 and @entity12098 among @entity1 with @entity6 were included. DATA EXTRACTION: Random effects meta-analysis (inverse variance method) was used to calculate the odds ratios for cardiovascular outcomes with @entity12585 use. The I(2 )statistic was used to assess statistical heterogeneity. RESULTS: Cardiovascular outcomes from 16 observational studies (4 case-control studies and 12 retrospective cohort studies), including 810,000 @entity12585 users, were evaluated after a detailed review of 189 citations. Compared with @entity12098 , use of @entity6170 was associated with a statistically significant increase in the odds of @entity583 (n = 15 studies; odds ratio 1.16, 95% confidence interval 1.07 to 1.24; P < 0.001; I(2) = 46%), @entity712 (n = 8; 1.22, 1.14 to 1.31; P < 0.001; I(2) = 37%), and @entity204 (n = 8; 1.14, 1.09 to 1.20; P < 0.001; I(2) = 0%). @entity15296 ( @entity10575 ), depending on the population at risk, suggest 170 excess @entity583 , 649 excess cases of @entity712 , and 431 excess deaths for every 100,000 @entity1 who receive @entity6170 rather than @entity12098 . CONCLUSION: Among @entity1 with @entity164 2 @entity6 , use of @entity6170 is associated with significantly higher odds of @entity712 , @entity583 , and @entity204 relative to @entity12098 in real world settings.

Comparative cardiovascular effects of XXXX : systematic review and meta-analysis of observational studies.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'heart failure'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'type 2 diabetes mellitus'] @entity12585 :: ('MESH:C089946', 'Chemical') :: ['thiazolidinedione'] @entity12098 :: ('MESH:C060836', 'Chemical') :: ['pioglitazone'] @entity12721 :: ('MESH:D045162', 'Chemical') :: ['thiazolidinediones'] @entity15296 :: ('MESH:D019553', 'Disease') :: ['Numbers needed to treat to harm'] @entity10575 :: ('OMIM:256810', 'Disease') :: ['NNH'] @entity164 :: ('MESH:D017827', 'Disease') :: ['type'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarctions', 'myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity6170 :: ('MESH:C089730', 'Chemical') :: ['rosiglitazone']
@entity12721 :: (MESH:D045162,Chemical) :: ['thiazolidinediones']
